Lantheus Medical Imaging parent company Lantheus Holdings reported a 53% increase in revenue in its second quarter, but also a higher net loss.
For the period (end-June 30), Lantheus had worldwide revenue of $101.1 million, up from $66.1 million in the second quarter of 2020. In quarterly highlights, sales of its Definity echocardiography contrast agent exceeded pre-COVID-19 levels, according to the company.
Lantheus reported a net loss, however, of $26.7 million, compared with a net loss of $7 million in the same period a year ago.
Looking ahead, Lantheus has slightly raised its full-year revenue and earnings estimates. The vendor now expects 2021 revenue will range between $395 million and $402 million, compared with the previous estimated range of $390 million to $400 million. Adjusted diluted earnings per share is also now projected to range between $0.38 and $0.42, up from prior guidance of $0.36 to $0.41.
